Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06496568 · ClinicalTrials.gov registry record · Phase 1
A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab, and Inavolisib Plus Pembrolizumab in PIK3CA-Mutated Cancers
A Phase 1 study of PIK3CA-Mutated Cancers, sponsored by Hoffmann-La Roche.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 8
- Study locations
NCT06496568 is a Phase 1 study of PIK3CA-Mutated Cancers that is actively recruiting participants, run by Hoffmann-La Roche. The registered enrollment target is 30 participants. The trial reports 8 study locations across 6 states.
The verdict
NCT06496568, a Phase 1 study of PIK3CA-Mutated Cancers, is actively recruiting participants, sponsored by Hoffmann-La Roche.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of the study is to assess the safety and efficacy of inavolisib as a single-agent, in combination with atezolizumab, and in combination with pembrolizumab in participants with phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (PIK3CA)-mutated cancers, including previously treated head and neck squamous cell carcinoma (HNSCC).
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Atezolizumab
- DRUG Inavolisib
Study Locations (8)
California
- Moores Cancer Center at UC San Diego Health - La Jolla
- California Cancer Associates for Research & Excellence, Inc. - San Marcos
Other
- Seoul National University Hospital - Seoul
- Samsung Medical Center - Seoul
Tennessee
- Vanderbilt-Ingram Cancer Ctr - Nashville
British Columbia
- BC Cancer Vancouver Centre - Vancouver
Ontario
- Princess Margaret Cancer Center - Toronto
Quebec
- Jewish General Hospital - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-12-11 |
| Est. Completion | 2028-09-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06496568
The ClinicalTrials.gov registry entry for NCT06496568 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with PIK3CA-Mutated Cancers appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT06496568 reports 8 study locations spanning 6 distinct geographic areas - top geographies include California, Other, Tennessee.
Frequently Asked Questions
What is clinical trial NCT06496568 about?
NCT06496568 is a clinical study titled "A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab, and Inavolisib Plus Pembrolizumab in PIK3CA-Mutated Cancers". The purpose of the study is to assess the safety and efficacy of inavolisib as a single-agent, in combination with atezolizumab, and in combination with pembrolizumab in participants with phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (PIK3CA)-mutated cancers, includi...
What is the current status of trial NCT06496568?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2023-12-11. Estimated completion is 2028-09-28.
What conditions does trial NCT06496568 study?
This clinical trial studies the following conditions: PIK3CA-Mutated Cancers.
What interventions are being tested in trial NCT06496568?
The interventions under investigation include: Pembrolizumab (DRUG), Atezolizumab (DRUG), Inavolisib (DRUG).
Who is sponsoring clinical trial NCT06496568?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06496568 being conducted?
This trial has 8 study locations across California, Tennessee, British Columbia, Ontario, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.